ANIX Quote, Financials, Valuation and Earnings

ImmunityBio, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of -209.83%. Anixa Biosciences, Inc.'s return on equity of -64.77% beat ImmunityBio, Inc.'s return on equity of --.

Anixa Biosciences, Inc. has a consensus price target of $9.00, signalling upside risk potential of 108.77%. On the other hand ImmunityBio, Inc. has an analysts' consensus of $10.20 which suggests that it could grow by 345.42%. Given that ImmunityBio, Inc. has higher upside potential than Anixa Biosciences, Inc., analysts believe ImmunityBio, Inc. is more attractive than Anixa Biosciences, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison ImmunityBio, Inc. has a beta of -0.028, suggesting its less volatile than the S&P 500 by 102.834%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunityBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. ImmunityBio, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than ImmunityBio, Inc. quarterly revenues of $32.1M. Anixa Biosciences, Inc.'s net income of -$2.3M is higher than ImmunityBio, Inc.'s net income of -$67.3M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while ImmunityBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 23.73x for ImmunityBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexeo Therapeutics, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of --. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Lexeo Therapeutics, Inc.'s return on equity of -86.99%.

Anixa Biosciences, Inc. has a consensus price target of $9.00, signalling upside risk potential of 108.77%. On the other hand Lexeo Therapeutics, Inc. has an analysts' consensus of $19.40 which suggests that it could grow by 107.49%. Given that Anixa Biosciences, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Lexeo Therapeutics, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Lexeo Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexeo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Lexeo Therapeutics, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Lexeo Therapeutics, Inc. quarterly revenues of --. Anixa Biosciences, Inc.'s net income of -$2.3M is higher than Lexeo Therapeutics, Inc.'s net income of -$20.3M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Lexeo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus -- for Lexeo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of 16.24%. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Anixa Biosciences, Inc. has a consensus price target of $9.00, signalling upside risk potential of 108.77%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -33.96%. Given that Anixa Biosciences, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Puma Biotechnology, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Anixa Biosciences, Inc.'s net income of -$2.3M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 1.25x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Anixa Biosciences, Inc.'s net margin of 38.89%. Anixa Biosciences, Inc.'s return on equity of -64.77% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Anixa Biosciences, Inc. has a consensus price target of $9.00, signalling upside risk potential of 108.77%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that Anixa Biosciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Anixa Biosciences, Inc. has a beta of 0.488, which suggesting that the stock is 51.221% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Anixa Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Anixa Biosciences, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Anixa Biosciences, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Anixa Biosciences, Inc.'s net income of -$2.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Anixa Biosciences, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anixa Biosciences, Inc. is -- versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.